Palmitoylethanolamide Effects on Intraocular Pressure After Nd:YAG Laser Iridotomy: An Experimental Clinical Study

Purpose: The purpose of this article was to evaluate whether the anti-inflammatory agent palmitoylethanolamide (PEA) can counteract the increase of intraocular pressure (IOP) that may occur after neodymium-doped: yttrium aluminum garnet (Nd:YAG) laser iridotomy. Methods: Fifteen patients underwent bilateral laser iridotomy (Visulas YAG III Laser; Zeiss) for the prevention of primary closed-angle glaucoma. The IOP was measured at the beginning of the study (t-1), after 15 days of pretreatment with placebo or PEA (t0), and at 15, 30, and 120 min after the iridotomy (t1, t2, t3). The pretreatment consisted of 2 tablets of placebo or PEA per day for 15 days. Results: The t-test did not show a significant difference between the preoperative mean values of IOP t - 1 and t0 in both the pretreatments. Analysis of variance/Tukey's test pointed out a significant increase of the postoperative IOP values in placebo pretreated patients (P <= 0.05), but not in those who were pretreated with PEA. The trend analysis confirmed the significant positive trend in placebo pretreatment. The parallelism test between the 2 regressions showed a significant difference for the slopes (P = 0.022) and not for the intercepts (P = 0.520). Conclusions: PEA can counteract the increase of IOP that occurs after iridotomy. It is likely that PEA controls the inflammatory process after iridotomy.